BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics develops oral cancer drug candidates that target KRAS and PI3Kα signaling. It last closed at $1.94 on Nov 17, down 2.02% on the day. The average 12-month price target from 9 analysts is $17.78 (+816.4% from the last close), with a high of $27.00 and a low of $9.00. Analyst consensus is Strong Buy, based on the latest ratings from 9 firms (9 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From BBOT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 9 analysts who set a price target on BBOT in the past 90 days. The average target is $17.78, with a high of $27.00 and a low of $9.00, compared with the last close of $1.94.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | Piper Sandler | Maintained | Buy | $15 |
| Nov 11 | Wedbush | Target lowered | Buy | $25 → $9 |
| Oct 21 | Morgan Stanley | Maintained | Buy | $13 |
| Oct 20 | Oppenheimer | Target lowered | Buy | $22 → $16 |
| Sep 11 | JP Morgan | Target lowered | Buy | $25 → $23 |
Technical Analysis
The stock is 24% below its 20 day and 74% below its 50 day average. It is 289% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the 52 week low at $1.93, and the nearest resistance the Pivot at $1.98.
| RSI (14) | 29.60 | Oversold below 30 | Oversold |
| MACD | -0.43 | Above its signal line | Bullish |
| Stochastic | 5.7 | Near the bottom of its range | Oversold |
| ADX (14) | 50.2 | Strong downtrend | |
| Williams %R | -99.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -129.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −16.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.27 | Typical daily range, 14.1% of price |
| RSI (14) | 21.69 | Oversold below 30 | Oversold |
| MACD | -1.86 | Below its signal line | Bearish |
| Stochastic | 0.9 | Near the bottom of its range | Oversold |
| ADX (14) | 37.7 | Trending down | |
| Williams %R | -99.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -94.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −60.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.93 | Typical daily range, 47.9% of price |
What happened before
See how BBOT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in BBOT in the last 90 days.
BBOT Institutional Ownership
Full report →- ▲56 buying vs 29 selling
- ▲Held by funds +1.4 pts
- ▲Funds holding +23
- ▲Superinvestors: 4 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 89 | 66 | +34.8% |
| In funds' top 10 | 5 | 4 | +25.0% |
| Held by funds | 75.1% | 73.7% | +1.4 pts |
| New / increased | 33 / 23 | 17 / 21 | +47.4% |
| Reduced / sold out | 20 / 9 | 15 / 18 | −12.1% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BBOT is in one of them and how their past BBOT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BBOT in an article yet. Here's the latest on the wider market.
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a biotechnology company based in South San Francisco, California, that is developing oral small molecule drugs for cancer. Its pipeline targets KRAS, a protein that is mutated in many cancers, and PI3Kα, a signaling protein that RAS proteins activate. The company is designing its drug candidates for patients with lung, breast, pancreatic and colorectal cancers, and it is testing them in early stage clinical trials.
- Headquarters
- South San Francisco, CA



